cancer weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of cancer weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Research
Patient enrolment begins in Reolysin clinical trial
October 25th, 2005
Oncolytics Biotech Inc. (ONC, ONCY) announced that it has started patient enrolment in its U.S. clinical trial investigating the systemic delivery of Reolysin as a treatment for patients with advanced or metastatic solid tumors. The Principal Investigator for the trial is Dr. Sanjay Goel, assistant professor and attending physician in the Department of Medical Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, New York City. This clinical trial is an open-label, dose-escalation phase I study in which a single dose of Reolysin will be administered intravenously to patients diagnosed with selected advanced or metastatic solid...
Source: cancer weekly (2005-10-25)
|
